| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ten large-cap standouts—including Maplebear, Tower Semiconductor, Eli Lilly, On Holding, Albemarle, and key gold/silver miners—...
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $66 to $72.
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price ta...
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...
RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and an...